Jia Jin-Bin, Zhuang Peng-Yuan, Sun Hui-Chuan, Zhang Ju-Bo, Zhang Wei, Zhu Xiao-Dong, Xiong Yu-Quan, Xu Hua-Xiang, Tang Zhao-You
Liver Cancer Institute and Zhongshan Hospital, Fudan University, Shanghai 200032, China.
J Cancer Res Clin Oncol. 2009 Jun;135(6):847-54. doi: 10.1007/s00432-008-0521-0. Epub 2008 Dec 10.
To examine expression profile and prognostic significance of vascular endothelial growth factor (VEGF) and its receptors in hepatocellular carcinoma (HCC) and peritumoral tissue.
Expression of VEGF-A, VEGF-C, and VEGF receptor 1(VEGFR-1), VEGFR-2, and VEGFR-3 in tumor and peritumoral liver tissue was studied by immunohistochemistry in a tissue microarray from 107 patients with HCC. Unsupervised hierarchical cluster analyses were conducted to identify relevant clusters.
Staining of VEGF-A, VEGF-C, VEGFR-2, and VEGFR-3 was mostly found on the tumor cells and peritumoral hepatocytes, but VEGFR-1 was mostly expressed in stromal cells. In most of the cases, the expression of VEGF-A, VEGFR-1, VEGFR-2, and VEGFR-3 in was higher in peritumoral liver tissue, while VEGF-C expression was higher in tumor. Unsupervised hierarchical clustering analysis identified four prognostically different clusters, of which cluster A was classified into the "poor prognosis group," and the other three clusters were classified into the "good prognosis group" (P = 0.047). Further analysis with a set of seven markers reproduced the same four cluster groups with significantly different recurrence free probability (RFP) (P = 0.018), and the low RFP group was associated with more intrahepatic satellite lesions. Multivariate analysis showed that classification defined by seven biomarkers was of prognostic significance (P = 0.000).
Expression of VEGF and its receptors was higher in peritumoral tissue than in tumor in HCC. Seven biomarkers predicted patients' RFP, which consisted of tumoral expression of VEGF-A, VEGFR-1, and VEGF-C as well as peritumoral expression of VEGF-A, VEGFR-1, VEGFR-2, and VEGFR-3.
研究血管内皮生长因子(VEGF)及其受体在肝细胞癌(HCC)和癌旁组织中的表达谱及预后意义。
采用免疫组织化学方法,在107例HCC患者的组织芯片上研究肿瘤及癌旁肝组织中VEGF-A、VEGF-C、血管内皮生长因子受体1(VEGFR-1)、VEGFR-2和VEGFR-3的表达。进行无监督分层聚类分析以识别相关聚类。
VEGF-A、VEGF-C、VEGFR-2和VEGFR-3的染色主要见于肿瘤细胞和癌旁肝细胞,但VEGFR-1主要表达于基质细胞。在大多数病例中,癌旁肝组织中VEGF-A、VEGFR-1、VEGFR-2和VEGFR-3的表达较高,而肿瘤中VEGF-C的表达较高。无监督分层聚类分析确定了四个预后不同的聚类,其中A聚类被归类为“预后不良组”,其他三个聚类被归类为“预后良好组”(P = 0.047)。用一组七个标志物进行的进一步分析重现了相同的四个聚类组,其无复发生存概率(RFP)有显著差异(P = 0.018),低RFP组与更多肝内卫星灶相关。多变量分析表明,由七个生物标志物定义的分类具有预后意义(P = 0.000)。
HCC中癌旁组织VEGF及其受体的表达高于肿瘤组织。七个生物标志物可预测患者的RFP,包括肿瘤中VEGF-A、VEGFR-1和VEGF-C的表达以及癌旁组织中VEGF-A、VEGFR-1、VEGFR-2和VEGFR-3的表达。